NEW YORK--(BUSINESS WIRE)--OrbiMed is pleased to announce the promotion of David Bonita, M.D., to General Partner. David joins the firm’s six existing General Partners, Sven H. Borho, Carl Gordon, Jonathan Silverstein, Carter Neild, Geoffrey Hsu and Scot Stevens.
Since joining OrbiMed in 2004, David has led numerous transformative investments in innovative biopharmaceutical and medical device companies, including Loxo Oncology, Tricida, Cryterion Medical, and Therachon SAS, among others.
“David’s investments have contributed significantly to the financial returns enjoyed by OrbiMed’s clients, but more importantly his companies have discovered and developed numerous therapies that treat life-threatening unmet medical needs.” stated Jonathan Silverstein, a Managing Partner of OrbiMed.
“David’s promotion to General Partner is a recognition of his extraordinary contributions to the firm in recent decades,” stated Managing Partner Carl Gordon. “We look forward to his growing organizational leadership in the years to come.”
David can be reached at (212) 739-6400 or BonitaD@OrbiMed.com
OrbiMed is a leading healthcare investment firm, with $13 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, utilizing a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed maintains offices in New York City, San Francisco, Shanghai, Hong Kong, Mumbai and Herzliya. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies.